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Retention of Supraspinal Delta-like Analgesia
and Loss of Morphine Tolerance in
d Opioid Receptor Knockout Mice
nervous system, with high levels in the olfactory bulb,
striatum, cortex, hippocampal formation, pons, spinal
cord, and dorsal root ganglion (Mansour et al., 1993),
reflects this potentially broad range of functions, while
prenatal expression patterns (Zhu et al., 1998) suggest
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targets for the development of novel analgesic agents
(Rapaka and Porreca, 1991). In addition to these func-
tions, d receptors also have been implicated in the pro-Summary
duction of morphine tolerance. For example, low doses
of the d receptor antagonist naltrindole can prevent tol-Gene targeting was used to delete exon 2 of mouse
erance to m receptor agonists (Abdelhamid et al., 1991;DOR-1, which encodes the d opioid receptor. Essen-
Hepburn et al., 1997) without compromising the antino-tially all 3H-[D-Pen2,D-Pen5]enkephalin (3H-DPDPE)
ciceptive activity of morphine.and 3H-[D-Ala2,D-Glu4]deltorphin (3H-deltorphin-2) bind-
Pharmacological studies have suggested at least twoing is absent from mutant mice, demonstrating that
d receptor subtypes. The d1 receptor subtype is prefer-DOR-1 encodes both d1 and d2 receptor subtypes. Ho-
entially activated by the agonist [D-Pen2,D-Pen5]en-mozygous mutant mice display markedly reduced spi-
kephalin (DPDPE) and antagonized by [D-Ala2,Leu5,nal d analgesia, but peptide d agonists retain supraspi-
Cys6]enkephalin (DALCE), while the d2 receptor is pre-nal analgesic potency that is only partially antagonized
ferentially activated by [D-Ala2,D-Glu4]deltorphin (del-by naltrindole. Retained DPDPE analgesia is also dem-
torphin-2) (Mattia et al., 1991, 1992; Hiller et al., 1996)onstrated upon formalin testing, while the nonpeptide
and antagonized by naltrindole-59-isothiocyanate (59-NTII).d agonist BW373U69 exhibits enhanced activity in
This classification is further supported by analgesicDOR-1 mutant mice. Together, these findings suggest
(Mattia et al., 1992; Tiseo and Yaksh, 1993), adenylylthe existence of a second delta-like analgesic system.
cyclase (Olianas and Onali, 1995), and antisense ap-Finally, DOR-1 mutant mice do not develop analgesic
proaches (Standifer et al., 1994; Rossi et al., 1997). How-tolerance to morphine, genetically demonstrating a
ever, the relationship of these two d receptor subtypescentral role for DOR-1 in this process.
to the cloned DOR-1 gene remains unclear, and it is not
known whether either or both d1 and d2 activities areIntroduction
derived from the DOR-1 locus (Raynor et al., 1994).
Multiple components of the murine opioid system,Pharmacologically, three major classes of opioid recep-
including genes encoding MOR-1 (Matthes et al., 1996;tors have been proposed, each of which is capable of
Sora et al., 1997; Tian et al., 1997; Roy et al., 1998;modulating pain (Herz, 1993; Pasternak, 1993). Of these
Schuller et al., 1999), KOR-1 (Simonin et al., 1998), thereceptors, the d receptor (DOR-1; also oprd1) was the
preproenkephalin (pre-PENK) precursor (Konig et al.,first one cloned (Evans et al., 1992; Kieffer et al., 1992),
1996), and the b-endorphin domain of the proopiomela-followed soon afterward by the m receptor (MOR-1;
nocortin (POMC) precursor (Rubinstein et al., 1996),oprm1) and the k receptor (KOR-1; oprk1) (see Kieffer,
have been disrupted by gene targeting. Analysis of these1995, for review). These three classical opioid receptors
mutant strains of mice thus far suggests that each com-are typical G protein receptors, with seven putative
ponent has a distinct role in a wide range of physiologicaltransmembrane regions, and are highly homologous to
functions, including analgesia, stress responses, hema-each other (Kieffer, 1995).
topoiesis, and reproduction. In this study, we have usedd receptors have been associated with several physio-
gene targeting to produce d receptor±deficient mice andlogical functions, including analgesia (Heyman et al.,
explore d receptor actions in these knockout (KO) mice.1988), tolerance (Abdelhamid et al., 1991; Kest et al.,
1996), and reproduction (Zhu and Pintar, 1998). The dis-
tribution of d receptors in multiple regions of the adult Results/Discussion
The murine DOR-1 gene was altered by replacing exon‖ To whom correspondence should be addressed (e-mail: pintar@
mbcl.rutgers.edu). 2 with a neomycin resistance cassette (Figure 1a). The
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Figure 1. Gene Targeting of DOR-1
(a) Gene targeting construct for DOR-1 disruption. A 2.1 kb SpeI±BamHI fragment derived from the intronic region 59 to exon 2 and a 4.8 kb
KpnI±HindIII fragment beginning in the intron region 39 to exon 2 of the mouse DOR-1 gene were cloned into the pBs±KO vector containing
neomycin and thymidine kinase selection markers. Thus, in the targeting construct, exon 2 was replaced with the neomycin resistance gene.
Genomic Southern blot was used to detect successful targeting events. When the neomycin gene was introduced into the endogenous DOR-1
locus, the KpnI site located 39 of exon 2 was deleted, which changed the size of the KpnI fragment from 12 kb to 14 kb, as detected by an
external probe.
(b and c) Southern blot analysis of KpnI-digested genomic DNA from electroporated ES cells (b) and mouse tail DNA from offspring of mice
heterozygous for the mutated DOR-1 allele (c). Abbreviations: neo, neomycin resistance gene; HSV-TK, thymidine kinase gene from the herpes
simplex virus. Genotypes: 1/1, wild-type; 1/2, heterozygous; and 2/2, homozygous.
targeting vector was introduced into CCE embryonic Saturation analysis revealed little observable 3H-DPDPE
and 3H-deltorphin-2 binding in brain membranes fromstem (ES) cells from the 129/SvEv mouse line, and three
homozygous mutant mice (Figure 2b). Autoradiographictargeted ES cells lines were identified by Southern blot-
analysis of 3H-DPDPE binding also revealed a dramaticting (Figure 1b). Two targeted ES lines were injected
reduction of binding throughout the homozygous mu-into blastocysts and gave rise to germline-transmitting
tant mouse brain, with no area showing obvious bindingmale chimeras. Heterozygotes for this mutated allele
above background (Figure 2c). These results indicatewere mated, and mice homozygous for the altered allele
that the DOR-1 locus encodes both of the pharmacologi-were present in offspring (Figure 1c). Genotyping showed
cally defined receptors d1 and d2. Therefore, the differentthat the d-deficient offspring were present in the ex-
properties of the d1 and d2 receptor subtypes must arisepected Mendelian frequency (1/1, 26.2%; 1/2, 49.7%;
from this locus and could result from differential post-and 2/2, 24.1%) (n 5 370 offspring). No obvious devel-
translational modification of the DOR-1-encoded recep-opmental abnormalities were observed in the homozy-
tor protein, alterations in the molecular environment ofgous mutant mice. DOR-1 mutant mice appear healthy
the receptor protein, or possibly even splice variants,and are similar in size to wild-type litter mates. Both
as suggested by DOR-1 antisense mapping studiesmale and female homozygous mice are fertile and pro-
(Rossi et al., 1997).duce litters of normal size, indicating that the high level
Genetic disruption of DOR-1 did not significantly influ-of d expression seen in the trophoblast giant cells (Zhu
ence the expression of other opioid receptors or endog-and Pintar, 1998) is not essential for the successful com-
enous opioid peptide genes. No significant differencespletion of pregnancy.
in the levels of binding among the wild-type, heterozy-
gous, or homozygous mice were observed with m
DOR-1 Immunoreactivity and d1 and d2 Binding Are (3H-[D-Ala2,N-MePhe4,Gly-ol5]enkephalin [3H-DAMGO])
Abolished in DOR-1 Mutant Mice (1/1: Kd, 3.73 nM and Bmax, 209.7 fmol/mg protein; 2/2:To determine whether any DOR-1-derived protein, trans- Kd, 4.18 nM and Bmax, 246.4 fmol/mg protein) or k (3H-D-
lated from low levels of residual DOR-1 transcription (5a,7a,8b)-(1)-N-methyl-N-{7-1-pyrrolidinyl)-1-oxaspiro
(see below) could be detected in DOR-1 mutant mice, [4, 5]dec-8-yl}benzeneacetamide [3H-U69,593]) (1/1:
we performed immunocytochemical experiments using a Kd, 1.16 nM and Bmax, 23.29 fmol/mg protein; 1/2: Kd,
DOR-1 antiserum directed against exon 1±derived N-ter- 1.19 nM and Bmax, 22.66 fmol/mg protein; 2/2: Kd, 1.09
minal sequences of DOR-1 (amino acids 3±17; Arvidsson nM and Bmax, 25.55 fmol/mg protein) receptor ligands.
et al., 1995). Immunostaining was absent throughout In situ hybridization of the mRNA encoding all three
the brain of DOR-1 KO mice (Figure 2a), indicating the opioid receptors and the endogenous opioid peptide
absence of any detectable DOR-1-derived translation precursor genes PENK, POMC, and prodynorphin (PDYN)
product, and was significantly reduced in heterozygous were examined in adult brain (Figure 2d). As expected,
mice (data not shown). exon 2 DOR-1 transcripts were absent in the 2/2 mutant
d receptor binding in brain membrane fractions from mice, although low residual levels (,15%1/1) of
DOR-1 (1/1), DOR-1 (1/2), and DOR-1 (2/2) mutant direct DOR-1 exon 1 to DOR-1 exon 3 transcripts were
mice was analyzed using both the d1-preferring ligand characterized by Northern and PCR analysis (Figures 2e
and 2f). These transcripts do not appear to be translated3H-DPDPE and the d2-preferring ligand 3H-deltorphin-2.
Disruption of the DOR-1 Gene
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Figure 2. Characterization of Opioid Systems in DOR-1 KO Mice
(a) Immunocytochemical analysis of DOR-1 KO mice. Immunofluorescent confocal images of DOR-1 immunoreactivity in the pallidum (left)
and parabrachial nucleus (right) from DOR-1 (1/1) and DOR-1 (2/2) mice, respectively. Abundant DOR-1 immunoreactivity is observed in
wild-type mice but is virtually eliminated in sections from the homozygous DOR-1 mutant. Scale bar, 200 mm.
(b) d receptor binding sites in DOR-1 (1/1), DOR-1 (1/2), and DOR-1 (2/2) mouse brain are shown in Scatchard plots of 3H-DPDPE and
3H-deltorphin-2 binding to brain membranes from mice of the indicated genotype. Bmax (fmol/mg protein) and Kd (nmol) are indicated. Data
are representative of four separate determinations for each ligand. See the Experimental Procedures for detailed procedures.
(c) Autoradiographic mapping of DPDPE binding to brain sections. Wild-type (A, C, and E) and homozygous DOR-1 KO (B, D, and F) brains
were coembedded and incubated with 5 nM 3H-DPDPE. Results indicate that DPDPE binding is dramatically reduced throughout the neuroaxis,
including regions such as the olfactory bulb (compare A and B), caudate-putamen (compare C and D), and cortex (compare A, C, and E with
B, D, and F), which express relatively high levels of d receptor binding.
(d) In situ hybridization analysis of d, m , and k receptor and PENK, POMC, and PDYN genes in adult brains of DOR-1 (1/1) and DOR-1 (2/2)
mice. In the left panel, dark-field images show that exon 2 DOR-1 transcripts are absent in the mutant mice, while the distributions of m and
k receptor mRNAs in the mutant are similar to those of the wild-type. In the right panel, dark-field images show that mRNA expressions of
opioid peptide precursors PENK, POMC, and PDYN in DOR-1 (2/2) mice brain are similar to those of DOR-1 (1/1). Abbreviations: an, arcuate
nucleus; cp, caudate-putamen; ot, olfactory tubercle.
(e) Northern analysis of d receptor gene expression in adult brains of DOR-1 (1/1) and DOR (2/2) mice. Upper panel shows that both 8.5
and 11 kb DOR-1 transcripts are markedly decreased in DOR (2/2) brains (combined total is ,15% of DOR (1/1), as estimated by NIH
image). In the lower panel, ethidium bromide±stained gel shows that similar amounts of RNA were applied to each lane.
(f) RT-PCR of RNA isolated from DOR-1 (1/1) and DOR-1 (2/2) adult brain. RT-PCR using two different primer sets spanning DOR-1 exon
1 and exon 3 show that DOR-1 transcripts in DOR-1 (1/1) brain contain exon 2 (lanes 2 and 4), whereas transcripts present in DOR-1 (2/2)
brain lack exon 2 (lanes 3 and 5). Lanes 1 and 6 show a molecular weight marker. DOR-1 cDNA amplified with primer sets 1 and 2 served as
a positive control (lanes 7 and 8, respectively).
Primer set 1 is expected to amplify a 758 nucleotide fragment if exon 2 is present (wild-type and cDNA), and a 408 nucleotide fragment
if exon 2 is absent (758±350). Exon 1, 59 primer: GGAGCCCGTAGTGCCTCGTCC (nucleotide position, 142±162) and exon 3, 39 primer:
CGATTGATGTCCACCAGCGTCC (nucleotide position, 878±899). Primer set 2 is expected to amplify a 706 nucleotide fragment if exon 2 is
present, and a 356 nucleotide fragment if exon 2 is absent (706±350). Exon 1, 59 primer: CTCGTCAACCTCTCGGACGCC (nucleotide position,
73±93) and exon 3, 39 primer: CCTTGGAACCGGACAGCAGACG (nucleotide position, 757±778).
Abbreviations: c, cortex; cp, caudate-putamen; h, habenula; p, preoptic area; t, thalamus.
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Figure 3. Delta-Related Analgesia in DOR-1-Deficient Mice
(a and b) DPDPE analgesia in DOR-1 KO mice. Cumulative dose±response curves were generated in groups of mice (n $ 20) given DPDPE
administered either i.t. (a) or i.c.v. (b). Tailflick latencies were determined prior to drug administration and 15 min afterward. The ED50 value
for DPDPE following i.t. administration in the wild-type mice was 300 ng (95% confidence interval, 208±434 ng) for 1/2 mice, and the ED50
was 820 ng (510 ng±1.32 mg); for 2/2 mice, the ED50 was 1.83 mg (99 ng±3.38 mg). The rightward shift was 6.1-fold (p , 0.05).
(c) Deltorphin-2 analgesia in DOR-1-deficient mice. Groups of mice (n 5 15) received deltorphin-2 either i.t. (15 mg) or i.c.v. (20 mg) and were
tested for analgesia 15 min later. Statistical significance was determined by the Fischer exact test.
(d) BW373U86 analgesia in DOR-1 KO mice. Groups of mice received BW373U86 (60 ng, i.c.v. [n 5 6], 60 mg, i.t. [n 5 6], and 30 mg/kg, s.c.
[n 5 10]), and analgesia was assessed 5, 10, or 30 min later, respectively, in the radiant heat tailflick assay. The response in the KO group
was significantly greater than that of the wild-type group following both i.c.v. and s.c. administration (p , 0.01).
(Figure 1a) and, even if translated to a small degree, The insensitivity of DPDPE analgesia to m-selective an-
tagonists (Heyman et al., 1987) and its reduction by onlywould encode a completely altered protein structure
(see Experimental Procedures). In contrast, the distribu- antisense probes targeting DOR-1 (Standifer et al., 1994;
Rossi et al., 1997) initially indicated the importance oftions of all of the other mRNAs were qualitatively and
semiquantitatively similar (Figure 2d). Thus, DOR-1 ex- DOR-1-derived receptors in this response. We thus
tested the responses to these compounds followingpression does not appear to exert any regulatory control
on the transcription of genes encoding other opioid re- both intrathecal (i.t.) and intracerebroventricular (i.c.v.)
administration. DOR-1 homozygous mice were mark-ceptors and endogenous ligands. Independent regula-
tion of opioid system components has also been noted edly less sensitive to the d agonist DPDPE given i.t.,
although analgesia could be elicited at high-DPDPEfollowing disruptions of the m (Matthes et al., 1996;
Schuller et al., 1999) and k (Simonin et al., 1998) receptor doses, with an ED50 .6-fold higher than in wild-type
mice (Figure 3a). Spinal deltorphin-2 analgesia was alsogenes. This effect on only d receptor expression thus
provided the opportunity to characterize d receptor func- markedly diminished in the KO mice (Figure 3c), indicat-
ing a major contribution of DOR-1 to spinal analgesia.tions in DOR-1 KO mice that retain generally normal
expression of many other opioid system components. However, both DPDPE (Figure 3b) and deltorphin-2 (Fig-
ure 3d) retained their analgesic activity, with no reduc-
tion in potency, following supraspinal i.c.v. administra-Spinal d Analgesia Is Lost and Supraspinal Analgesia
Retained in DOR-1 Mutant Mice tion in the DOR-1 KO mice. Thus, these data indicate
that there are analgesic systems for classical d agonistsWe next explored analgesia in DOR-1 mutant mice. In
initial experiments, no differences in baseline tailflick that can be mediated through receptors other than DOR-1.
We next assessed the activity of a nonpeptide d anal-latencies were observed among the wild-type, heterozy-
gous, and homozygous groups using either the standard gesic, BW373U86 (Chang et al., 1993). Given i.c.v., virtu-
ally no analgesic response was elicited in wild-typelamp intensity, with latencies between 2 and 3 s, or a
reduced lamp intensity that produced latencies of z8 s mice, as had previously been shown (Wild et al., 1993).
In contrast, robust analgesia was observed in DOR-1(data not shown). We then explored the action of several
d agonists. d receptor±selective peptides, such as KO, with all mice tested not only exhibiting analgesia
(Figure 3d) but also reaching maximal analgesic cut-offDPDPE and deltorphin-2, are effective analgesics both
spinally and supraspinally (Heyman et al., 1987, 1988). times. When administered i.t., BW373U86 did not elicit
Disruption of the DOR-1 Gene
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DOR-1 KO mice, it was not as effective as in the wild-
type animals (Figure 5a). Similar results were observed
when the hot plate test was instead used to monitor
analgesia (Figure 5b). Again, naltrexone reversed the
analgesic response in all groups, while naltrindole signif-
icantly blocked the response in wild-type mice but not
in littermate heterozygous or homozygous mice.
Antisense approaches also distinguished the residual
supraspinal DPDPE analgesia from that normally elicited
in wild-type mice. Thus, a DOR-1 antisense probe tar-
geting exon 3, which had previously been shown to
reduce d ligand binding (Standifer et al., 1994), signifi-
cantly blocked supraspinal DPDPE analgesia in wild-
Figure 4. Formalin Testing in DOR-1 KO Mice type mice but not in heterozygous or homozygous
Formalin was administered via hindpaw injection to DOR-1 KO mice DOR-1 mutant mice (Figure 6), indicating that any residual
following i.c.v. injection of either DPEPE (8 mg) (n 5 4) or saline
transcription of DOR-1 exon 3 is not contributing to this(n 5 4) 15 min earlier. The response was monitored for 30 min
analgesia. While these findings confirm a role for DOR-1and indicates that the second phase of the formalin response is
in supraspinal DPDPE analgesia in wild-type mice, theysignificantly reduced by DPDPE in the DOR-1 mutant mice. Signifi-
cance was assessed by ANOVA. also indicate that the residual supraspinal DPDPE anal-
gesia seen in the KO animals is due to a receptor other
than DOR-1, a conclusion also consistent with the par-
tial, rather than complete, sensitivity of the residualanalgesia in either wild-type mice or DOR-1 homozy-
analgesia to naltrindole. Moreover, the enhanced activ-gous mutants, even following a 60 mg injection (Figure
ity described above of i.c.v. and peripheral BW373U863d). Thus, both peptide and nonpeptide d agonists elicit
in DOR-1 mutant mice suggests that the absence ofanalgesia in DOR-1 KOs following i.c.v., but not i.t., ad-
DOR-1 increases the sensitivity of this novel secondaryministration. We finally tested the response of wild-type
d analgesic system, which can both mediate continuedand mutant mice to systemic BW373U86 administration.
DPDPE and deltorphin-2 supraspinal analgesia andGiven systemically, this compound also had little effect
dramatically enhance the efficacy of at least one non-in wild-type mice and elicited a maximal analgesic re-
peptide d agonist. These observations indicate that non-sponse of only 10% at 30 mg/kg. Heterozygous mice
peptide agonists, such as BW373U86, likely act predom-were more sensitive, with 30% responding, while homo-
inantly on this secondary system though we cannot atzygous mutant mice developed significantly more anal-
present distinguish whether this novel d system is un-gesia than wild-type mice (Figure 3d).
masked or upregulated following DOR-1 ablation.We also explored the activity of DPDPE in the formalin
Although the DOR-1 KO mice contained no observ-test in DOR-1 KO mice. The appearance of the first and
able 3H-DPDPE or 3H-deltorphin-2 binding under the tra-second phases of enhanced licking and flinching that
ditional binding conditions used for these studies, wefollow hindpaw formalin administration were present in
did observe low levels of 3H-naltrindole binding with anthe DOR-1 KO mice and were not significantly different
affinity (Kd, 7.1 nM) z10-fold lower than that of traditionalfrom those seen in littermate wild-type mice (data not
d receptor binding in wild-type mice (Kd, 0.54 nM) (datashown). Since the formalin response can be reduced by
not shown). This low-affinity 3H-naltrindole binding siteexogenous DPDPE (Calcagnetti et al., 1988), the analge-
may correspond to the receptor responsible for the re-sic properties of this compound in conjunction with for-
sidual d analgesia.malin administration were tested in DOR-1 KO mice.
To summarize, several lines of evidence indicate thatDPDPE (8 mg) given i.c.v. virtually eliminated the second
a novel naltrexone-reversible mechanism which is notphase of the formalin response (Figure 4). Thus, DPDPE
blocked by subclass-specific opioid antagonists medi-analgesic activity in the DOR-1 KO mice can also be
ates retained DPDPE and deltorphin-2 analgesia, as welldemonstrated in an analgesic model distinct from ther-
as enhanced BW373U86 analgesia, in DOR-1 KO mice.mal nociception.
These include differential sensitivity to naltrindole, aWe next chose to investigate in detail one of the delta-
heightened response to BW373U86, and differentiallike responsesÐi.c.v. DPDPE analgesiaÐexhibited by
sensitivity to an exon 3 oligonucleotide that does notDOR-1 mutant mice. We first explored the sensitivity of
suppress DPDPE analgesia in DOR-1 KO as it does inthe retained i.c.v. DPDPE analgesia to opioid receptor
wild-type mice. Based on these data, we suggest thatantagonists. The residual supraspinal DPDPE analgesia
d analgesia in wild-type mice is mediated predominatelywas effectively blocked in all genotypes by naltrexone,
through DOR-1 systems, consistent with its sensitivitya general opioid receptor antagonist (Figure 5a), con-
to both naltrindole and antisense probes based uponfirming that the analgesia is opioid in nature. Conversely,
DOR-1. In contrast, an upregulated (or unmasked), sec-neither the m-selective antagonist b-funaltrexamine
ondary d system is responsible for the residual d analge-(b-FNA) nor the k-specific drug norbinaltorphimine (nor-
sia in DOR-1 KO mice, which explains its insensitivityBNI) blocked DPDPE supraspinal analgesia in any group
toward the same antisense probe and the distinct(Figure 5a). As expected, the d-selective antagonist nal-
patterns of response to both d agonists (such astrindole (Portoghese et al., 1988) significantly reduced
BW373U86) and antagonists (such as naltrindole), com-DPDPE analgesia in wild-type mice. However, although
naltrindole partially reduced DPDPE analgesia in the pared with wild type.
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Figure 5. Sensitivity of DPDPE Supraspinal Analgesia to Selective Opioid Receptor Antagonists
(a) In the tailflick assay, groups of mice (n 5 20) received a fixed dose of DPDPE (8 mg i.c.v.) alone or following administration of the opioid
antagonists b-FNA (40 mg/kg, s.c.), naltrexone (1 mg/kg, s.c.), naltrindole (20 mg/kg, s.c.), or nor-BNI (10 mg/kg, s.c.). All antagonists were
administered 15 min prior to DPDPE, with the exception of b-FNA, which was administered 24 hr prior to treatment. Analgesia was expressed
as the percentage of mice responding. Statistical significance was determined by the Fischer exact test.
(b) In the hot plate assay, groups of mice (n 5 10) received a fixed dose of DPDPE (8 mg, i.c.v.) alone or with naltrexone (1 mg/kg, s.c.) or
naltrindole (20 mg/kg, s.c.) 15 min prior to treatment. Naltrexone significantly antagonized DPDPE analgesia in all cohorts. However, naltrindole,
a selective d receptor antagonist, significantly blocked DPDPE analgesia only in the wild type. Statistical significance was determined by two-
tailed t-test, with a 95% confidence interval.
Characterization of Non-Delta Analgesia days (Figure 7d), while some heterozgyous mice became
and Development of Tolerance tolerant over this period. The lack of tolerance develop-
in DOR-1 KO Mice ment is similar to that seen with morphine, although
The disruption of DOR-1 did not alter the analgesic ef- the conclusions are less clear since the ability of the
fectiveness of the other classes of opioid analgesics. receptor mediating DPDPE analgesia in the DOR-1 KO
The m agonists morphine (Figure 7a) and morphine- mice to exhibit tolerance under the present dosing para-
6b-glucuronide, the k1 agent U50,488H, and the k3 drug digm is unknown. Nonetheless, these data indicate that
nalaxone benzoylhydrazone (Figure 7b) all maintained DOR-1 may be critical to the development of tolerance
their analgesic activity in the DOR-1 KO mice. These to opioid agonists besides morphine. The importance
data demonstrate that d expression is not required for of DOR-1 circuitry in the development of tolerance in
either the development or maintenance of circuitry un- vivo is further indicated by analysis of a novel KO mouse
derlying their analgesic responses. line lacking met-enkephalin peptides, derived from
Finally, we examined the role of d receptors in mor- PENK, that constitute the major DOR-1 ligand in vivo.
phine tolerance (Figures 7c and 7d). In contrast to wild- In these mice, the ability to develop tolerance to both
type animals, in which the analgesic response to a fixed morphine and DPDPE is also completely abolished, indi-
morphine dose was lost within 5 days, DOR-1 KO mice cating that an enkephalin±DOR-1 ligand±receptor sys-
failed to demonstrate tolerance following daily adminis- tem is likely an integral component of the pathway(s)
tration of morphine (5 mg/kg, subcutaneously [s.c.]) for 8 mediating tolerance (A. G. P. S. et al., unpublished data).
days (Figure 7c). After 10 days days of chronic morphine Taken together, these studies provide genetic evi-
dosing, cumulative dose±response curves revealed a dence for a unique role for d receptors in the central
significant 2.8-fold shift to the right of the morphine
ED50 in the wild-type mice. In contrast, the potency of
morphine in the DOR-1 KO mice was unchanged follow-
ing chronic morphine (Table 1) and thus was identical
to that observed in naive, wild-type mice. These results
confirm and extend in a genetic model the importance
of DOR-1 in morphine tolerance implied by earlier stud-
ies in which morphine tolerance was blocked by either
low doses of naltrindole, which selectively antagonized
d receptors (Hepburn et al., 1997), or by antisense tar-
geting of DOR-1 (Kest et al., 1996). In both prior cases,
however, the complete blockage of tolerance develop-
ment that was evident in the DOR-1 KO model was not
observed.
Since supraspinal DPDPE analgesia was exhibited by
Figure 6. DOR-1 Antisense Effect on DPDPE i.c.v. AnalgesiaDOR-1 KO mice (see above), we also examined whether
Groups of mice (n $ 10) received saline, a DOR-1 exon 3±directedtolerance to DPDPE developed in these mice. The anal-
oligodeoxynucleotide, or a mismatch oligonucleotide (5 mg, i.c.v.)gesic response to chronic DPDPE in wild-type mice, like
on days 1, 3, and 5. On day 6, all mice were tested with DPDPE (8
the response to morphine, was lost completely within 4
mg, i.c.v.), and analgesia was assessed. The exon 3 antisense probe
days, indicating the development of tolerance. In con- was effective in DOR (1/1) mice but did not reverse DPDPE analge-
trast, the ability of DPDPE to elicit analgesia in homozy- sia in DOR-1 KOs. Significance was analyzed by the Fisher exact
test.gous DOR-1 KO mice remained unchanged for at least 6
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Figure 7. Analgesic Action of Non-Delta-Selective Opiates and Opioid Tolerance in DOR-1 KO Mice
Groups of mice (n 5 10) received morphine at indicated doses (a) or M6G (12.5 ng, i.c.v. or 12.5 ng, i.t.), U50,488 (5 mg/kg, s.c.), or NalBzoH
(50 mg/kg, s.c.) (b). Mice receiving M6G were tested for analgesia 15 min later, and mice treated with morphine, U50,488, or NalBzoH were
tested for analgesia 30 min later. Significance was analyzed by the Fisher exact test.
(c) Groups of mice (n 5 20 per group) received morphine (5 mg/kg, s.c.) daily for 10 days. Analgesia was tested at the indicated times. After
10 days of morphine treatment, the wild-type mice exhibited a significant decrease in morphine analgesia, whereas the homozygote group
exhibited no change in analgesia.
(d) Groups of mice (n 5 10 per group) received DPDPE (8 mg, i.c.v.) daily for 5 days. Analgesia was tested at the indicated times. DPDPE
analgesia in wild-type mice was lost by the fourth day, while the response in the DOR-1 homozygous mice was unaltered.
nervous system. Our results indicate that DOR-1 en- opioid receptors and the central role of the d receptor
in in vivo action of the opioid system.codes both the d1 and d2 subtypes and significantly ex-
tend antisense studies implicating DOR-1 in d analgesia
(Standifer et al., 1994; Rossi et al., 1997). Equally impor-
Experimental Procedurestant, characterization of the DOR-1 KO mice has also
uncovered a novel d analgesic system not previously
Gene Targeting and Production of Mutant Miceobserved. Finally, these investigations have documented
A DOR-1 genomic clone was isolated from a Swiss Webster 129/
the critical importance of d receptors in the development ReJ mouse genomic library after screening with a full-length (1.8
of opioid tolerance. These observations provide new kb) DOR-1 cDNA (a gift from Dr. Chris Evans, University of California,
Los Angeles) probe generated by the random primed digoxigeninperspectives for understanding the pharmacology of
DNA labeling method (Boehringer Mannheim). This clone contained
exons 2 and 3 of DOR-1. A 2.1 kb SpeI±BamHI fragment correspond-
ing to the 59 untranslated region right before exon 2 of DOR-1 and aTable 1. Effects of Chronic Morphine Administration in Wild-
4.8 kb KpnI±HindIII fragment corresponding to the 39 region outsideType and DOR-1 KO Mice
exon 2 of DOR-1 were subcloned into a targeting construct con-
Morphine ED50 (mg/kg, s.c.) taining the neomycin resistance cassette and the HSV-TK gene
(95% Confidence Limits) (thymidine kinase gene from the herpes simplex virus). The latter
fragment contains exon 3 of DOR-1. Deletion of exon 2 eliminatesChronically
sequences encoding amino acids extending from the beginning ofNaive Mice Treated Mice Shift
intracellular loop 1 through transmembrane 4 (TM4) and introduces
Wild-type (1/1) 4.8 (3.9, 5.9) 13.4 (11.6, 15.4) 2.8 a frameshift into the DOR-1 coding region that would completely
DOR-1 knock-out (2/2) 4.3 (3.0, 6.0) 3.7 (2.9, 4.7) 0.9 disrupt the sequence downstream of Arg-76 and eliminate additional
TM domains and G protein binding sites if any translation occurred
Groups of mice (n 5 10) were used to determine ED50 values in wild- of residual transcripts containing direct splicing of DOR-1 exon 1
type or DOR-1 knockout mice. Groups were then treated daily with
to DOR-1 exon 3. The targeting vector was linearized and introduced
morphine (5 mg/kg, s.c.), and ED50 values were determined again into ES cells by electroporation. ES cells were selected for homolo-
after 10 days with a cumulative dose±response paradigm. Signifi-
gous recombination by culture in medium containing G418 and 2
cance was determined by the lack of overlap of 95% confidence
mM gancyclovir on days 2±7 following electroporation. DNA ex-
limits. The shift in the wild-type mice was significant, while that of
tracted from the selected clones was digested with KpnI andthe knockout mice was not. The experiment was repeated twice.
screened by Southern blotting using an external 0.6 kb HindIII±DraII
Neuron
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fragment 39 to the region included in the targeting construct. Screen- were determined by Scatchard analysis using the LIGAND program
of Munson and Rodbar (Munson and Rodbar, 1980).ing of all of the available ES cell clones isolated following electropor-
ation identified three correctly targeted clones, which were subse-
quently injected into C57B16/J blastocysts to generate chimeras.
Receptor AutoradiographyGermline transmitters derived from two targeted ES cell lines were
DORs were visualized in brain sections following receptor autoradi-identified and used to establish lines of DOR-1 mutant mice. Off-
ography (Unterwald, 1994). Briefly, brains from DOR-1 (1/1) andspring of germline-transmitting chimeras were genotyped as de-
DOR-1 (2/2) mice were coembedded in OTC and fresh frozen, andscribed above. Heterozygous mice were crossed to C57Bl6/J mice,
10 mm sections were prepared. Sections were preincubated for 30and littermate males, generally from matings of F2 and F3 generation
min in 50 mM Tris HCl (pH 7.4) at room temperature. Sections wereheterozygous mice, were used in essentially all behavioral experi-
then incubated in the same buffer containing 5 nM 3H-DPDPE forments. A few more recent experiments have used littermates from
2 hr at 218C. Adjacent sections were incubated under the sameheterozygous/heterozygous matings expanded from F4 and F5 gen-
conditions in a solution containing radiolabeled ligand in the pres-eration backcrosses to C57Bl6/J.
ence of 10 mM naloxone to assess nonspecific binding. Sections
were then washed in ice-cold 50 mM Tris HCl (6 3 20 s), dried underImmunocytochemistry
a stream of cold air, and stored at room temperature for 24 hr.Mice were perfused and processed for immunohistochemistry as
Labeled tissue sections were then exposed to tritium-sensitivepreviously described (Arvidsson et al., 1995). After perfusion fixation
Hyperfilm-3H for 12 weeks and subsequently developed using D-19.(4% paraformaldehyde and 0.2% picric acid in 0.1 M phosphate
buffer (pH 6.9), the brains were removed and placed in 10% sucrose
overnight. Cryostat sections (14 mm) were thaw mounted onto gela-
Analgesia Testingtin-coated slides. Incubation in primary antiserum (anti-mouse
Deltorphin-2 was synthesized by the Core Facility at MemorialDOR-1 3±17 [1:1000]; Arvidsson et al., 1995) was carried out at 48C
Sloan-Kettering Cancer Center and purified by high-pressure liquidovernight followed by incubation in secondary antisera (cyanine 3.18
chromatography, and its structure was verified by mass spectros-[1:200]; Jackson Immunoresearch) for 1 hr at room temperature. All
copy. Naltrexone, b-FNA, nor-BIN, morphine sulfate, morphine-images were acquired with a BioRad MRC1000 confocal micro-
6b-glucuronide, DPDPE, and U50,488 were gifts from the Researchscope equipped with an argon laser.
Technology Branch of the National Institute on Drug Abuse. Nalox-
one benzoylhydrazone (NalBzoH) was synthesized as described
In Situ Hybridization previously (Luke et al., 1988). Naltrindole was purchased from Re-
Cryostat brain sections were prepared from both wild-type and search Biochemicals International. Male mice from heterozygous/
homozygous DOR-1 mutant mice and hybridized as described heterozygous matings of F2 and F3 generation DOR-1 (1/2) mice
(Zheng and Pintar, 1995). 33P-UTP-labeled single-stranded RNA were used in essentially all analgesic tests. Drugs were administered
probes were synthesized and purified in vitro from the plasmid vec- i.c.v. (Haley and McCormick, 1957) or i.t. via lumbar puncture (Hylden
tors harboring the appropriate cDNA sequences. The DOR-1 probe and Wilcox, 1980). Analgesia of male mice was assessed by either
was synthesized from an exon 2±derived 282 bp BalI±SmaI cDNA the tailflick or the hot plate assay. The radiant heat tailflick assay
fragment. The m receptor probe was synthesized from a 346 bp utilized a light intensity that produced baseline latencies ranging
fragment (nucleotides 237 to 108) of the m receptor cDNA (a gift from 2 to 3 s. A 10 s cutoff was imposed to minimize tissue damage.
from Dr. Christopher Evans, University of California, Los Angeles). Analgesia or antinociception was defined as a doubling or greater
The KOR-1 probe was synthesized from a 376 bp PstI±EcoRI frag- of the baseline latency for an individual mouse. Group comparisons
ment (nucleotides 172 to 548) of the k receptor cDNA (a gift from were performed by the Fischer exact test. The hot plate was set at
Dr. Graeme I. Bell). The PENK RNA probe was synthesized from a 528C, producing baseline latencies ranging from 16 to 18 s. A 40 s
520 bp PstI fragment of PENK cDNA. The POMC probe was synthe- cutoff was imposed to minimize tissue damage. Statistical differ-
sized from a 220 bp POMC cDNA fragment (exon 1 and exon 2). ences were determined by a two-tailed t-test with a 95% confidence
The PDYN probe was synthesized from a PDYN cDNA fragment interval. ED50 values with 95% confidence limits were determined
(nucleotides 292±1900) (provided by Dr. James Douglass, Vollum with the Bliss program, as previously described (Rossi et al., 1997).
Institute, Portland, OR). For formalin testing, mice were injected with 20 ml of 5% formalin
into the hindpaw. After formalin injection, time spent in licking, flinch-
Ligand Binding on Brain Homogenates ing, and rearing events was recorded for 30 min and plotted in 5
Wild-type, heterozygous, and homozygous d receptor mutant min time intervals. Statistical significance was determined by AN-
mouse brains were homogenized in 60 vol of 50 mM Tris HCl (pH OVA. The DOR-1 exon 3 antisense oligodeoxynucleotide was based
7.4) at 48C. The resulting homogenates were centrifuged at 30,000 3 on the mouse DOR-1 sequence (Evans et al., 1992; Kieffer et al.,
g for 15 min at 48C, and the pellets were resuspended in 60 vol of 1992) and corresponded to nucleotide positions 662±681 (AACACG
the same buffer. The homogenates were centrifuged at 30,000 3 g CAGATCTTGGTCAC). The mismatch antisense probe was CGAGC
for 15 min. The resulting pellets were homogenized in 60 vol of the GCAACAGCTGCAT. These oligodeoxynucleotides were synthe-
same buffer and then incubated for 30 min at 378C in a water bath sized by Midland Certified Reagent (Midland, TX), purified, and dis-
in order to dissociate endogenous ligands from the receptors. After solved in 0.9% saline. Mice received i.c.v. injections of oligonucleo-
a third centrifugation, the pellets were resuspended in 60 vol of 50 tides (5.0 mg in 2.0 ml) on days 1, 3, and 5 and were tested on day
mM Tris HCl (pH 7.4). Protein concentrations were determined by 6, as previously described (Standifer et al., 1994; Rossi et al., 1997).
the Lowry procedure (Sigma).
Aliquots (z0.3 mg protein) of freshly prepared homogenates were
incubated with eight concentrations of 3H-DPDPE (120 min at 258C), Acknowledgments
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